Leiden, The Netherlands, September 12, 2006. Biotech company Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM) (PHARM.AS) announced today that it has appointed Dr. Bruno Giannetti as its Chief Operations Officer effective December 1, 2006. In addition, the Company has nominated Dr. Giannetti as a member of the Board of Management, subject to shareholder approval at the next Extraordinary Meeting of Shareholders.
Dr. Giannetti (54) is currently the CEO of AM-Pharma (The Netherlands). He has more than 25 years experience in the pharmaceutical industry through roles with Madaus, Germany, (Head of Clinical Research), Immuno, Austria (world-wide Vice-President Marketing and Medical Information), Coopers & Lybrand, Switzerland/UK (management consultant for pharmaceutical R&D projects) and Verigen AG, Germany (Chief Operations Officer and subsequently President and CEO). He is the founder of CRM, a well established European Clinical Research Organization specialized in international pharmaceutical clinical research. He holds a PhD in chemistry and a MD PhD degree in medicine from the University of Bonn.
"I am excited to join Pharming at this very important phase of the Company," commented Dr. Giannetti. "Pharming owns a world-class technology platform for the development of recombinant human proteins. The Company has made great progress in bringing its first product Rhucin® to market. I believe that I can make a significant contribution to the further growth of the Company through my knowledge of and experience in clinical development and marketing of innovative pharmaceutical products."
Dr. Francis Pinto, CEO and Chairman of the Board of Management commented: "Pharming has been fortunate to recruit Dr. Giannetti in this position. I am convinced that, through his long and successful international experience, he will be a valuable addition to the management of Pharming. I strongly endorse his nomination for membership of the Board of Management."
Pharming expects to provide further information regarding date and venue of the Extraordinary Meeting of Shareholders (needed to appoint Dr. Giannetti as a member of the Board of Management) before October 15, 2006.
Background on Pharming Group NV Pharming Group NV is developing innovative protein products for the treatment of genetic disorders, specialty products for surgical indications, intermediates for various applications and food products. Pharming has two products in late stage development - Rhucin® (recombinant human C1 inhibitor) for hereditary angioedema (under review by EMEA) and human lactoferrin for use in functional foods (GRAS notification under review by US FDA). The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, as well as technology and processes for the purification and formulation of these products. Additional information is available on the Pharming website, http://www.pharming.com.
This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements. The press release also appears in Dutch. In the event of any inconsistency, the English version will prevail over the Dutch version.
Carina Hamaker Sarah MacLeod Samir Singh Investor Voice Financial Dynamics Pharming Group NV T: +31 (0)6 537 49959 T: +44 (0)20 7269 7148 T: +1 908 720 6224 T: +31 (0)71 524 7431 T: +44 (0)7747 602 739 T: +1 800 333 1476
Viðskiptablaðið er 25 ára og af því tilefni býðst nýjum áskrifendum að kaupa áskrift á 50% afslætti.
Afmælisverðið er aðeins 2.500 krónur.
Tilboðið er fyrir nýja áskrifendur. Núverandi áskrifendur geta bætt við sig áskrift á þessu verði. Gildir í 4 mánuði. Áskrifendur fá Viðskiptablaðið, Frjálsa verslun og Fiskifréttir sent ásamt vefaðgangi að vb.is og fiskifrettir.is